David Risinger, an analyst from Leerink Partners, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target is €120.00.
David Risinger has given his Buy rating due to a combination of factors that highlight Sanofi’s potential for growth and innovation. A key element in his analysis is the promising outlook for amlitelimab, an anti-OX40L antibody, which is being developed for multiple indications, including atopic dermatitis, asthma, and hidradenitis suppurativa. Sanofi has identified amlitelimab as one of its top pipeline assets, with potential peak sales exceeding €5 billion, particularly in the atopic dermatitis market.
Risinger notes that while there is some caution regarding the timing of the asthma data readout, the broader potential of amlitelimab across various conditions presents significant upside. The drug’s ability to address underserved populations and its competitive efficacy profile could enhance its market position. Additionally, Sanofi’s strategic focus on amlitelimab and its ongoing trials in other indications, such as alopecia areata and celiac disease, further support the Buy rating, reflecting confidence in Sanofi’s long-term growth prospects.
In another report released on March 4, Berenberg Bank also reiterated a Buy rating on the stock with a €120.00 price target.
SNYNF’s price has also changed slightly for the past six months – from $116.830 to $121.292, which is a 3.82% increase.
Questions or Comments about the article? Write to editor@tipranks.com